Dopamine (Intropin)

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.

Also Known As:

Networked: 16016 relevant articles (602 outcomes, 1756 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Volkow, Nora D: 34 articles (11/2015 - 10/2002)
2.	Abi-Dargham, Anissa: 33 articles (04/2015 - 09/2003)
3.	Bezard, Erwan: 31 articles (09/2015 - 04/2003)
4.	Brooks, David J: 30 articles (01/2013 - 10/2002)
5.	Björklund, Anders: 29 articles (10/2015 - 04/2002)
6.	Stoessl, A Jon: 28 articles (01/2015 - 06/2002)
7.	Grace, Anthony A: 27 articles (03/2015 - 08/2002)
8.	Wang, Gene-Jack: 26 articles (11/2015 - 10/2002)
9.	Seeman, Philip: 26 articles (10/2014 - 03/2002)
10.	Lees, Andrew J: 25 articles (12/2015 - 10/2002)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 10/01/2003 - "Dopamine replacement therapy (DRT) is the most effective treatment for Parkinson's disease (PD); it provides substantial benefit for most patients, extends independence, and increases survival. " 10/01/1999 - "The paradoxical hyperdopaminergia in the DAT KO mice despite a marked decrease in TH and dopamine levels suggests a parallel to Parkinson's disease implying that blockade of DAT may be beneficial in this condition." 04/01/2011 - "Cerebral dopamine neurotrophic factor (CDNF) is a novel evolutionary conserved protein which can protect and restore the function of dopaminergic neurons in the rat model of Parkinson's disease, suggesting that CDNF might be beneficial for the treatment of Parkinson's disease. " 09/01/2004 - "The primary pathology of Parkinson's disease is the degeneration of dopaminergic neurons in the nigrostriatal pathway, resulting in a significant reduction in striatum dopamine concentration which is responsible for the altered motor functions. " 01/01/2002 - "The primary pathology of Parkinson's disease is the degeneration of dopaminergic neurons in the nigrostriatal pathway, resulting in a significant reduction in striatum dopamine concentration which is responsible for the altered motor functions. "
2.	Schizophrenia (Dementia Praecox) 01/01/1977 - "Several different classes of drugs effective in the treatment of schizophrenia were potent inhibitors of the stimulation by dopamine of the enzyme from these various regions. " 12/21/1999 - "The major findings of this study are: 1. biopsies from patients with schizophrenia showed a significantly reduced ability to attach to the culture slide: 29.9% of patient biopsies attached compared to 73.5% of control biopsies; 2. biopsies from patients with schizophrenia had a significantly greater proportion of cells undergoing mitosis: 0.69% in the patients compared to 0.29% in the controls; and 3. dopamine (10 microM) significantly increased the proportion of apoptotic cells in the control cultures but significantly decreased the proportion in patients' cultures." 10/01/2013 - "In treating schizophrenia, 65% to 80% occupancy of dopamine D₂ receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. " 10/04/2002 - "The development of new dopamine D(3) receptor selective antagonists is premised on the potentially improved therapeutic treatment of psychosis like schizophrenia. " 01/01/1988 - "Future studies in which attempts are made at using both plasma and CSF HVA to enhance neurochemical and clinical correlates may help to advance our understanding of the contributions of specific CNS dopamine systems to schizophrenia."
3.	Dyskinesias (Dyskinesia) 03/01/2005 - "Thus, this study suggests that diminished buffering capacity for dopamine could play a role in the development of dyskinesias, and that an endogenous mechanism might exist that ameliorates dyskinesias." 01/01/2013 - "Preclinical studies in dopamine-denervated animals have contributed to the modeling of these abnormal movements, but the precise neurochemical and functional mechanisms underlying these untoward effects are still elusive. " 01/01/2011 - "Our study demonstrated that the A2ARs in the putamen were increased in the PD patients with dyskinesia, and also suggest that the A2ARs in the putamen compensate for the asymmetrical decrease of dopamine in drug-naïve PD patients and that antiparkinsonian therapy increases the A2ARs in the putamen. " 07/01/2008 - "The present study was aimed at assessing behavioral and biochemical correlates of intense or mild dyskinesia displayed by the different dopamine (DA) receptors stimulation in a rat model of PD. " 01/01/1988 - "The purpose of this study was to characterize the dopaminergic system in the mouse cerebellum and to determine whether the dyskinesia of the reeler mutant is accompanied by alterations in cerebellar and/or striatal dopamine binding. "
4.	Parkinsonian Disorders (Parkinsonism) 01/01/1996 - "Behavioral measures of parkinsonism that are more clinically relevant than rotometry have been developed for rats with severe unilateral dopamine depletions, and the validity of these measures is supported by reports that these parkinsonian symptoms are attenuated by drugs that are effective in the clinical setting. " 07/01/1992 - "Furthermore, the data emphasize the importance of hypothalamic pathology in the development of Parkinsonism and suggest that intrahypothalamic administration of dopamine blocking agents might be useful in the treatment of Parkinsonism." 11/01/2011 - "However, the use of experimental models of parkinsonism has helped understand the motor complications associated with pulsatile dopamine replacement. " 09/01/1998 - "Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review." 11/26/1992 - "Bilateral implantation of fetal mesencephalic tissue can induce substantial long-term functional improvement in patients with parkinsonism and severe dopamine depletion and is accompanied by increased uptake of fluorodopa by the striatum. "
5.	Heart Failure 10/01/2014 - "The Dopamine in Acute Decompensated Heart Failure II study enrolled 161 patients with AHF and found no improvement in clinical outcomes with the addition of dopamine. " 03/01/1994 - "The plasma concentration of free dopamine decreased, whereas the concentration of conjugated dopamine increased as heart failure improved. " 01/01/2012 - "The aim of the study was to assess the effect of intravenous dopamine infusion on the function of pituitary gland in patients with acute cardiac failure. " 12/01/2010 - "Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial." 06/01/1995 - "Clinical studies showed that the plasma level of dopamine sulfate decreased significantly during the acute phase of heart failure, whereas that of free dopamine increased. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Norepinephrine (Noradrenaline)
3.	Serotonin (5 Hydroxytryptamine)
4.	Antipsychotic Agents (Antipsychotics)
5.	Dobutamine
6.	Epinephrine (Adrenaline)
7.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
8.	Bupropion (Wellbutrin)
9.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
10.	Dihydroxyphenylalanine (Dopa)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Transplants (Transplant)
3.	Drug Therapy (Chemotherapy)
4.	Denervation
5.	Resuscitation